Invivoscribe Launched New Oncology Sequencing Suite
The platform helps research laboratories analyze gene rearrangements to improve the study of blood-based cancers.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe advanced molecular testing technology will lead to better overall healthcare outcomes?
Invivoscribe has introduced the LymphoTrack Flex suite, a next-generation sequencing system designed to support advanced oncology research. The technology aims to provide clinical laboratories with a more standardized workflow for identifying specific gene rearrangements.
Why it matters
As demand for high-throughput oncology research grows, laboratories need more efficient and sensitive tools to ensure reproducible results. This system offers a streamlined approach for clonality assessment and research into minimal residual disease.
The suite integrates seven molecular targets including IGHV leader and various immunoglobulin and T-cell receptor gene rearrangements into a single NGS workflow. These results are generated via massively parallel multiplexing.
The players
Invivoscribe
A San Diego-based biotechnology company with over 30 years of experience providing diagnostic tools and laboratory services for oncology and immunology.
The details
The platform functions by employing a bioinformatics engine that performs sequence analysis on targeted gene rearrangements. Laboratories can choose between local desktop-based analysis or a centralized environment for high-throughput testing. By consolidating multiple targets into one workflow, the system aims to improve testing efficiency and reproducibility in research settings.
Timeline
Invivoscribe announced the launch of LymphoTrack Flex on October 6, 2026.
Health Landscape
This development follows the broader shift toward next-generation sequencing (NGS) workflows in clinical research. It marks an advancement in standardizing the tools used to identify complex genetic markers in blood-based cancers.
While this tool is designed for laboratory research rather than direct patient testing, it may influence the speed and precision of diagnostic reports patients receive in the future. If you are participating in a clinical trial, you may wish to discuss with your oncologist how advanced testing methods affect your care plan.
The takeaway
The move toward centralized, high-throughput sequencing is designed to enhance the reproducibility of oncology test results. Patients should note that advancements in laboratory technology are increasingly supporting more precise and efficient clinical assessments.
Further reading
For more on the evolution of diagnostic testing, visit our Cancer section.
Source note: This article includes information reported by The Kingston Whig-Standard.
Live Poll
Do you believe advanced molecular testing technology will lead to better overall healthcare outcomes?
